Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0) who have indications for kidney preservation surgery but have difficulty in preserving the kidney (R.E.N.A.L. score \>= 10).

NCT Number	NCT07389629
Lead Sponsor	Sun Yat-sen University
Conditions	Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
Enrollment	25 participants
Start Date	2025-11-21
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-05